KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 2, 2026-- KalVista Pharmaceuticals, Inc.